Recent changes reflected in this handbook
⌄
| Date | Guideline | What changed | Pages |
|---|---|---|---|
| Sep 2026 | CMS TAVR coverage (NCD) | Symptomatic severe AS covered without CED; asymptomatic AS only in approved studies | Aortic stenosis |
| Aug 2025 | ESC/EACTS valvular heart disease | TAVI for age ≥70 (tricuspid valve, suitable anatomy); earlier AVR in selected asymptomatic severe AS | Aortic stenosis |
| Aug 2025 | AHA/ACC high blood pressure | "Urgency" → severe hypertension; no IV drugs for the number in inpatients without organ damage; staged lowering | Hypertensive emergency, Aortic dissection |
| 2023 | Duke-ISCVID + ESC endocarditis | PET/CT and cardiac CT as major criteria; surgery as major criterion; oral step-down (POET) | Endocarditis |
| Jul 2026 | ACC ECDP — HFpEF | SGLT2i + finerenone backbone; GLP-1 RA / tirzepatide if BMI ≥30; β-blockers only with an indication | HFpEF |
| Jun 2026 | Second Universal Definition of HF | Less reliance on rigid EF cut-offs; cause and trajectory; new AHA/ACC HF guideline expected 2027 | HFrEF, HFpEF |
| Mar 2026 | Surviving Sepsis Campaign 2026 | NEWS/MEWS/SIRS over qSOFA; balanced crystalloids; prolonged-infusion β-lactams; MAP 60–65 if ≥65 y; no routine anaerobic coverage | Sepsis, Hypotension, Fever |
| Jan 2026 | AHA/ASA Acute Ischemic Stroke | Tenecteplase 0.25 mg/kg = alteplase as first line; EVT expanded | Stroke |
| Jul 2025 | IDSA complicated UTI | Afebrile cystitis in men = uncomplicated; 7-day courses; early oral switch | UTI |
| Jul 2025 | ATS CAP update | Steroids for severe CAP, not non-severe; short courses; lung ultrasound; viral-positive inpatients | CAP |
| 2025 | AHA ACLS | AF and flutter cardioversion start 200 J | AF, Flutter, Quick cards |
| Feb 2025 | ACC/AHA ACS | Ticagrelor/prasugrel preferred; LDL goal <70 (consider <55); complete revascularization in stable STEMI | STEMI, NSTE-ACS |
| 2024 | ADA/EASD hyperglycemic crises | New DKA/HHS criteria (glucose ≥200 or known DM; β-OHB ≥3.0) | DKA/HHS |
| 2024 | ACC/AHA peri-operative | BNP/NT-proBNP for risk; SGLT2i hold 3 days | Pre-op |
Review schedule
⌄
Every January, April, July, October: check ACC/AHA, ESC, IDSA, ATS, ADA, AASLD, ACG, KDIGO, SCCM, AHA/ASA for new guidelines → update pages → change the "Reviewed" date.
Coming next
⌄
S. aureus bacteremia · Myocarditis · Mitral regurgitation · HCM · Cardiac amyloid · C. difficile · Hypercalcemia · Hypokalemia/Mg/Phos · Lower GI bleed · Thyroid storm · TTP/HUS · Tumor lysis · Falls · Night calls: hypoxia, AMS, low urine output.